TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT02310867: Immunomodulation to Optimize Vascularized Composite Allograft Integration for Limb Loss Therapy

Sponsor: Linda Cendales · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 50 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$11,040,000

Rescue Site Savings

+$7,279,500

Unlock Full NCT02310867 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT02310867 Rescue Dossier →